Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kazuhiro Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Biomarkers, Tumor, Circulating MicroRNA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Platinum chemotherapy is the cornerstone of treatment for high‐grade serous ovarian cancer (HGSOC); however, validated biomarkers that can accurately predict platinum response are lacking. Based on their roles in the underlying pathophysiology, circulating microRNAs are potential, noninvasive biomarkers in cancer. In the present study, we aimed to evaluate the circulating miRNA profiles of patients with HGSOC and to assess their potential utility as biomarkers to predict platinum response.
Methods
Pretreatment serum samples collected from patients who received platinum chemotherapy for Stage III–IV HGSOC between 2008 and 2016 were analyzed using miRNA microarray. LASSO logistic regression analysis was used to construct predictive models for treatment‐free interval of platinum (TFIp).
Results
The median follow‐up was 54.6 (range, 3.5–144.1) months. The comprehensive analysis of 2588 miRNAs was performed in serum samples of 153 eligible patients, and predictive models were constructed using a combination of circulating miRNAs with an area under the receiver operating characteristic curve of 0.944 for TFIp >1 month, 0.637 for TFIp ≥6 months, 0.705 for TFIp ≥12 months, and 0.938 for TFIp ≥36 months. Each predictive model provided a significant TFIp classification ( p = 0.001 in TFIp >1 month, p = 0.013 in TFIp ≥6 months, p < 0.001 in TFIp ≥12 months, and p < 0.001 in TFIp ≥36 months).
Conclusion
Circulating miRNA profiles has potential utility in predicting platinum response in patients with HGSOC and can aid clinicians in choosing appropriate treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Institute for Advanced Research, Nagoya University, Nagoya, Japan.
- Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
- Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
ORCID-Profile: Akira Yokoi, Kosuke Yoshida, Yusuke Yamamoto
Zitieren
APA
Suzuki, K., Yokoi, A., Matsuzaki, J., Yoshida, K., Yamamoto, Y., Kato, T., Ishikawa, M., Ochiya, T., & Kajiyama, H. (2024). Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70251
Vancouver
Suzuki K, Yokoi A, Matsuzaki J, Yoshida K, Yamamoto Y, Kato T, et al. Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70251
BibTeX
@article{Suzuki2024,
author = {Suzuki, Kazuhiro and Yokoi, Akira and Matsuzaki, Juntaro and Yoshida, Kosuke and Yamamoto, Yusuke and Kato, Tomoyasu and Ishikawa, Mitsuya and Ochiya, Takahiro and Kajiyama, Hiroaki},
title = {Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70251}
}
EUVIMED